Literature DB >> 26387888

A Comprehensive Assessment Across the Healthcare Continuum: Risk of Hospital-Associated Clostridium difficile Infection Due to Outpatient and Inpatient Antibiotic Exposure.

Sara Y Tartof1, Gunter K Rieg2, Rong Wei1, Hung Fu Tseng1, Steven J Jacobsen1, Kalvin C Yu1.   

Abstract

BACKGROUND: Limitations in sample size, overly inclusive antibiotic classes, lack of adjustment of key risk variables, and inadequate assessment of cases contribute to widely ranging estimates of risk factors for Clostridium difficile infection (CDI).
OBJECTIVE: To incorporate all key CDI risk factors in addition to 27 antibiotic classes into a single comprehensive model.
DESIGN: Retrospective cohort study.
SETTING: Kaiser Permanente Southern California. PATIENTS: Members of Kaiser Permanente Southern California at least 18 years old admitted to any of its 14 hospitals from January 1, 2011, through December 31, 2012.
METHODS: Hospital-acquired CDI cases were identified by polymerase chain reaction assay. Exposure to major outpatient antibiotics (10 classes) and those administered during inpatient stays (27 classes) was assessed. Age, sex, self-identified race/ethnicity, Charlson Comorbidity Score, previous hospitalization, transfer from a skilled nursing facility, number of different antibiotic classes, statin use, and proton pump inhibitor use were also assessed. Poisson regression estimated adjusted risk of CDI.
RESULTS: A total of 401,234 patients with 2,638 cases of incident CDI (0.7%) were detected. The final model demonstrated highest CDI risk associated with increasing age, exposure to multiple antibiotic classes, and skilled nursing facility transfer. Factors conferring the most reduced CDI risk were inpatient exposure to tetracyclines and first-generation cephalosporins, and outpatient macrolides. CONCLUSIONS Although type and aggregate antibiotic exposure are important, the factors that increase the likelihood of environmental spore acquisition should not be underestimated. Operationally, our findings have implications for antibiotic stewardship efforts and can inform empirical and culture-driven treatment approaches.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26387888     DOI: 10.1017/ice.2015.220

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  15 in total

Review 1.  Impact of microbial derived secondary bile acids on colonization resistance against Clostridium difficile in the gastrointestinal tract.

Authors:  Jenessa A Winston; Casey M Theriot
Journal:  Anaerobe       Date:  2016-05-07       Impact factor: 3.331

2.  Recent Anti-Microbial Exposure Is Associated with More Complications after Elective Surgery.

Authors:  Christopher A Guidry; Puja M Shah; Zachary C Dietch; Nathan R Elwood; Elizabeth D Krebs; J Hunter Mehaffey; Robert G Sawyer
Journal:  Surg Infect (Larchmt)       Date:  2018-06-08       Impact factor: 2.150

Review 3.  Clostridium difficile Infection: An Epidemiology Update.

Authors:  Ana C De Roo; Scott E Regenbogen
Journal:  Clin Colon Rectal Surg       Date:  2020-02-25

4.  Why Does Doxycycline Pose a Relatively Low Risk for Promotion of Clostridioides difficile Infection?

Authors:  Dongyan Xu; Thriveen S C Mana; Jennifer L Cadnum; Abhishek Deshpande; Faezeh Afsari; Naseer Sangwan; Curtis J Donskey
Journal:  Pathog Immun       Date:  2022-06-21

5.  Ursodeoxycholic Acid (UDCA) Mitigates the Host Inflammatory Response during Clostridioides difficile Infection by Altering Gut Bile Acids.

Authors:  Jenessa A Winston; Alissa J Rivera; Jingwei Cai; Rajani Thanissery; Stephanie A Montgomery; Andrew D Patterson; Casey M Theriot
Journal:  Infect Immun       Date:  2020-05-20       Impact factor: 3.441

6.  Outcomes of Clostridioides difficile infection in adult cancer and non-cancer patients hospitalised in a tertiary hospital: a prospective cohort study.

Authors:  Bojana Milenković; Vesna Šuljagić; Aneta Perić; Viktorija Dragojević-Simić; Olivera Tarabar; Milomir Milanović; Vesna Putić; Diana Tomić; Branislava Miljković; Sandra Vezmar Kovačević
Journal:  Eur J Hosp Pharm       Date:  2021-02-12

7.  Hospital-level high-risk antibiotic use in relation to hospital-associated Clostridioides difficile infections: Retrospective analysis of 2016-2017 data from US hospitals.

Authors:  Ying P Tabak; Arjun Srinivasan; Kalvin C Yu; Stephen G Kurtz; Vikas Gupta; Steven Gelone; Patrick J Scoble; L Clifford McDonald
Journal:  Infect Control Hosp Epidemiol       Date:  2019-09-16       Impact factor: 6.520

8.  Evaluating the Effectiveness of an Antimicrobial Stewardship Program on Reducing the Incidence Rate of Healthcare-Associated Clostridium difficile Infection: A Non-Randomized, Stepped Wedge, Single-Site, Observational Study.

Authors:  Giulio DiDiodato; Leslie McArthur
Journal:  PLoS One       Date:  2016-06-16       Impact factor: 3.240

9.  Clostridium difficile bacteremia: Report of two cases in French hospitals and comprehensive review of the literature.

Authors:  Mouna Doufair; Catherine Eckert; Laurence Drieux; Come Amani-Moibeni; Liliane Bodin; Michel Denis; Jean Didier Grange; Guillaume Arlet; Frédéric Barbut
Journal:  IDCases       Date:  2017-03-28

Review 10.  Statin use and the risk of Clostridium difficile infection: a systematic review with meta-analysis.

Authors:  Raseen Tariq; Dhruvika Mukhija; Arjun Gupta; Siddharth Singh; Darrell S Pardi; Sahil Khanna
Journal:  Infect Drug Resist       Date:  2018-03-13       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.